STOCKSCOPE

Tivan (ASX: TVN) Advances Speewah Fluorite Project With $19.9M Cash, but Can It Secure Construction Funding?

Alison Elzayed

Alison Elzayed

Business & Finance Writer | StockScope

Published:5d ago
Tivan (ASX: TVN) Advances Speewah Fluorite Project With $19.9M Cash, but Can It Secure Construction Funding?

Tivan Limited (ASX: TVN) is advancing one of Australia's emerging fluorite development opportunities while expanding its copper-gold exploration activities in Timor-Leste. With $19.9 million in cash and strategic Japanese partners supporting its Speewah Fluorite Project, the company has several potential growth drivers.

However, substantial development expenditure and competing project commitments raise an important question: can Tivan secure the funding needed to transform its mineral assets into profitable operations without excessive shareholder dilution?

Key numbers

  • $19.925 million: Cash and cash equivalents at 30 September 2026.
  • 43.2 million tonnes at 8.3% CaF₂: Existing Speewah Fluorite Mineral Resource, including 27.7 million tonnes classified as Indicated.
  • 149,000 tonnes annually: Approximate acid-grade fluorspar production targeted under Speewah's March 2026 feasibility study.
  • $9.812 million: September-quarter net investing cash outflow, reflecting substantial project expenditure.
  • 6.87% copper and 24.7g/t gold: Peak surface sampling grades reported from Tivan's Timor-Leste exploration activities.

The latest development: Speewah moves towards its next commercial milestones

Tivan's 29 October 2026 Fluorine Forum presentation highlighted continued progress at the Speewah Fluorite Project in Western Australia.

The project contains an existing Mineral Resource of 43.2 million tonnes grading 8.3% calcium fluoride, comprising 27.7 million tonnes of Indicated material and 15.5 million tonnes classified as Inferred.

A higher-grade component of approximately 9.6 million tonnes at 20.6% calcium fluoride provides potential advantages for mine planning and processing.

The March feasibility study outlined an initial 10-year operating case targeting approximately 149,000 tonnes of acid-grade fluorspar annually.

Technical progress includes a completed mini-pilot programme that produced approximately 195 kilograms of acidspar at a weighted average grade of 98.6% calcium fluoride.

This exceeds the commonly referenced 97% acid-grade benchmark.

However, pilot-scale production does not establish commercial-scale recoveries, operating costs or profitability.

Tivan is progressing an updated Mineral Resource, maiden Ore Reserve and definitive feasibility study ahead of a potential final investment decision.

What stands out to us: Strategic partners strengthen Speewah's development case

Speewah benefits from strategic relationships involving Sumitomo Corporation, Japan's JOGMEC and ETFS Capital through its incorporated joint venture structure.

These relationships could support technical development, market access and financing.

However, the project's total economic value should not be confused with Tivan's attributable interest.

Future returns will depend on joint venture ownership, funding contributions, operating costs and the distribution of project cash flows.

Importantly, a project financing mandate does not represent fully committed construction funding.

The definitive feasibility study must establish credible capital requirements and sustainable operating economics before the project can advance towards commercial production.

Financially, Tivan reported $19.925 million in cash at September's end, alongside $9.812 million in investing cash outflows.

Operating cash outflow was $97,000, while financing inflows totalled $9.171 million.

The reported funding estimate of 2.30 quarters reflects historical expenditure rather than a guaranteed development runway.

What the company is doing now

Beyond Speewah, Tivan is preparing maiden drilling at the Scorpion Prospect within its Baucau Project in Timor-Leste.

The company received approval for preparatory civil works on 26 October, supporting a proposed six-hole diamond drilling campaign of up to 1,500 metres.

Drilling was targeted for early November, subject to the required environmental licence.

Earlier surface sampling returned grades reaching 6.87% copper and 24.7g/t gold, although no Mineral Resource has been established.

Tivan is also progressing its proposed Molyhil Tungsten Project joint venture and associated development drilling plans.

At Sandover, exploration has returned fluorite intersections including 20.3 metres at 18.9% calcium fluoride.

These programmes provide exploration opportunities but increase the demands on management and capital.

Insight: Can Speewah Deliver Returns Without Overstretching Tivan's Balance Sheet?

We think Speewah represents Tivan's strongest commercial opportunity, supported by an established fluorite resource, completed feasibility work and strategic Japanese partnerships. Its higher-grade mineralisation and technical progress provide a more credible development pathway than the company's earlier-stage exploration assets. However, substantial project expenditure remains a concern. The $19.9 million cash balance provides flexibility, but construction financing, joint venture obligations and future capital requirements remain unresolved. Our assessment is cautiously constructive on Speewah's development potential, while stronger confidence requires definitive project economics, committed funding and clarity on Tivan's attributable cash flows.

What happens next?

The immediate commercial catalysts are Speewah's updated Mineral Resource, maiden Ore Reserve and definitive feasibility study.

These milestones should provide greater clarity on mine planning, processing recoveries, capital expenditure and potential project returns.

Confirmation of construction financing arrangements will be particularly important.

Meanwhile, Scorpion's maiden drilling could establish whether its high-grade surface mineralisation extends into potentially significant copper-gold zones.

For shareholders, the central question is whether Tivan can prioritise its most advanced assets while managing development costs and financing requirements.

Speewah offers a credible pathway towards critical minerals production. Demonstrating commercially sustainable economics and securing the necessary construction capital remain the decisive tests.

Alison Elzayed

Alison Elzayed

(Business & Finance Writer | StockScope)

Alison Elzayed is an experienced business and financial writer with more than 10 years of experience in the publishing industry, having previously worked as an author with Bloomsbury Publishing, specialising in business and finance. Throughout her career, Alison has developed a strong understanding of financial markets, corporate developments, economic trends and investment-related topics. Her background in financial publishing has equipped her with the ability to research complex subjects and communicate them in a clear, accurate and engaging manner.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore
Market Briefings
Market Briefings

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore

Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...

Mark ElzayedMark Elzayed•
Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test
Biotech & Health
Biotech & Health

Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test

Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...

Danny AadDanny Aad•
Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?
Mining
Mining

Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?

A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...

Alison ElzayedAlison Elzayed•
Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?
Mining
Mining

Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?

Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...

Alison ElzayedAlison Elzayed•
Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet
Mining
Mining

Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet

Avenira Limited ASX: AEV has reached a significant financing milestone, with its $48.9 million rights issue providing fresh capital to advance the Wonarah Phosphate Project in the Northern T...

Alison ElzayedAlison Elzayed•
Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?
Biotech & Health
Biotech & Health

Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?

Mayne Pharma Group Limited ASX: MYX is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million. The tran...

Danny AadDanny Aad•
Loading more stories...